The Alpha-2A Adrenergic Receptor Gene -1291C/G Single Nucleotide Polymorphism is Associated with the Efficacy of Methylphenidate in Treating Taiwanese Children and Adolescents with Attention-Deficit Hyperactivity Disorder

키워드

참고문헌 (40)

1. Chan E, "Treatment of attention-deficit", hyperactivity disorder in adolescents: a systematic review, 2016, pp.315, 1997~2008
2. Rappley MD, "Clinical practice. Attention deficit-hyperactivity disorder", N Engl J Med, 352, pp.165~173 (2005)[DOI]
3. Arnsten AF, "The use of <TEX>$\alpha$<", TEX>-2A adrenergic agonists for the treatment of attention-deficit, Expert Rev Neurother, pp.2010, 10[DOI]
4. Arnsten AF, "Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder", Behav Brain Funct, 1, pp.2~ (2005)[DOI]
5. Arnsten AF, "Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions", Biol Psychiatry, 57, pp.1377~1384 (2005)[DOI]
6. Cinnamon Bidwell L, "Alpha-2 adrenergic receptors and attention-deficit", hyperactivity disorder, 2010, pp.12, 366~373
7. Alamo C, "Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (ADHD)", Actas Esp Psiquiatr, 44, pp.107~112 (2016)
8. Gamo NJ, "Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors", J Am Acad Child Adolesc Psychiatry, 49, pp.1011~1023 (2010)[DOI]
9. Stahl SM, "Mechanism of action of alpha 2A-adrenergic agonists in attention-deficit", hyperactivity disorder with or without oppositional symptoms, 2010, pp.71, 223~224
10. Hanwella R, "Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a metaanalysis", BMC Psychiatry, 11, pp.176~ (2011)[DOI]
11. Heal DJ, "The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety", Neuropharmacology, 57, pp.608~618 (2009)[DOI]
12. Wigal SB, "Efficacy and safety limitations of attention deficit hyperactivity disorder Pharmacotherapy in pediatric patients", J Pediatr, 154, pp.S13~S21 (2009)
13. Arnsten AF, "The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex", J Pediatr, 154, pp.S22~S31 (2009)
14. Volkow ND, "Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain", J Neurosci, 21, pp.RC121~ (2001)[DOI]
15. Del Campo N, "The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit", hyperactivity disorder, 2011, pp.69, e145~e157
16. Bonvicini C, "Attention-deficit hyperactivity disorder in adults: a systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies", Mol Psychiatry, 21, pp.872~884 (2016)[DOI]
17. Froehlich TE, "Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics", CNS Drugs, 24, pp.99~117 (2010)[DOI]
18. Zaiou M, "Cardiovascular pharmacogenetics: a promise for genomically-guided therapy and personalized medicine", Clin Genet, 91, pp.355~370 (2017)[DOI]
19. Steele M, "Remission versus response as the goal of therapy in ADHD: a new standard for the field", Clin Ther, 28, pp.1892~1908 (2006)[DOI]
20. Vaughan B, "Pharmacotherapy of pediatric attentiondeficit", hyperactivity disorder, 2012, pp.21, 941~955
21. Purper-Ouakil D, "Neurobiology of attention deficit", hyperactivity disorder, 2011, pp.69, 69R~76R
22. Levy F, "Applications of pharmacogenetics in children with attentiondeficit", hyperactivity disorder, 2014, pp.7, 349~356
23. Comings DE, "Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects", Clin Genet, 55, pp.160~172 (1999)[DOI]
24. Roman T, "Further evidence of the involvement of alpha-2A-adrenergic receptor gene (ADRA2A) in inattentive dimensional scores of attention-deficit", hyperactivity disorder, 2006, pp.11, 8~10
25. Cheon KA, "Association between homozygosity of a G allele of the alpha-2a-adrenergic receptor gene and methylphenidate response in Korean children and adolescents with attention-deficit", hyperactivity disorder, 2009, pp.65, 564~570
26. da Silva TL, "Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit", hyperactivity disorder-predominantly inattentive type, 2008, pp.115, 341~345
27. Polanczyk G, "Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit", hyperactivity disorder, 2007, pp.64, 218~224
28. Park S, "No significant association between the alpha-2A-adrenergic receptor gene and treatment response in combined or inattentive subtypes of attentiondeficit hyperactivity disorder", Pharmacopsychiatry, 46, pp.169~174 (2013)[DOI]
29. Dilek Unal, "Genetic Variations in Attention Deficit Hyperactivity Disorder Subtypes and Treatment Resistant Cases", PSYCHIATRY INVESTIGATION, 13(4), pp.427~433 (2016), 대한신경정신의학회[DOI]
30. Redinbo MR, "Human carboxylesterase 1: from drug metabolism to drug discovery", Biochem Soc Trans, 31, pp.620~624 (2003)[DOI]
31. Sun Z, "Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1", J Pharmacol Exp Ther, 310, pp.469~476 (2004)[DOI]
32. Nemoda Z, "Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD", Neuropharmacology, 57, pp.731~733 (2009)[DOI]
33. Zhu HJ, "Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis", Am J Hum Genet, 82, pp.1241~1248 (2008)[DOI]
34. Gau SS, "Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, Version IV Scale-Teacher Form", J Pediatr Psychol, 34, pp.850~861 (2009)[DOI]
35. Gau SS, "Psychometric properties of the Chinese version of the Swanson, Nolan, and Pelham, version IV scale-parent form", Int J Methods Psychiatr Res, 17, pp.35~44 (2008)[DOI]
36. Liu YC, "Norm of the Chinese Version of the Swanson, Nolan and Pelham, Version IV Scale for ADHD", Taiwan J Psychiatry, 20, pp.290~304 (2006)
37. Su Y, "Osmotic release oral system methylphenidate versus atomoxetine for the treatment of attentiondeficit", hyperactivity disorder in chinese youth: 8-week comparative efficacy and 1-year follow-up, 2016, pp.26, 362~371
38. Lario S, "MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene", Clin Genet, 51, pp.129~130 (1997)
39. Schmitz M, "Association Between Alpha-2a-adrenergic Receptor Gene and ADHD Inattentive Type", Biol Psychiatry, 60, pp.1028~1033 (2006)[DOI]
40. Webster LR, "Pharmacogenetics and personalized medicine in pain management", Clin Lab Med, 36, pp.493~506 (2016)[DOI]

관련 논문AI추천